Alzamend Neuro amends bylaws to lower stockholder quorum to 35%, creates Series C Preferred Stock

Alzamend Neuro, Inc.

Board reduced quorum for stockholder meetings from majority of outstanding shares to 35%.
Filed Certificate of Designation for Series C Convertible Preferred Stock with Delaware.
Series C issuance part of previously disclosed exchange and purchase agreement with a sophisticated investor.
Exchange of 97.7511 shares of Series A for Series C; up to 500 additional Series C shares to be sold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.